Back to News
Market Impact: 0.3
What Axsome Therapeutics (AXSM) Said on Its Q3 Earnings Call
Source: marketbeat.com
Corporate EarningsHealthcare & BiotechCompany Fundamentals
Axsome Therapeutics reported third-quarter revenue growth of 52% year over year, driven primarily by continued expansion of AUVELITY sales for major depressive disorder and Alzheimer's disease agitation.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.35
Ticker Sentiment
AXSM0.55
More News
- Marvell to buy Lumentum in $115 billion deal in AI data-center bet
- Palantir reports booming U.S. commercial revenue growth, topping government for first time
- Anthropic releases amended IPO prospectus with third-quarter financials
- Coinbase has been battered over the past month. Morgan Stanley says steer clear
- The AI boom is facing another supply crunch. This time it’s the amount of capital available to feed Silicon Valley’s endless need for cash
- Anthropic to Spend $895 Billion in the Years Ahead